Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

NCT03507738 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: MT-5625 low dose
BIOLOGICAL: MT-5625 middle dose
BIOLOGICAL: MT-5625 high dose
BIOLOGICAL: Rotarix
BIOLOGICAL: Placebo

Sponsor

Tanabe Pharma Corporation